The traditional stepwise approach in the management of patients with open-angle glaucoma—moving from medication to laser-based procedures to surgical options, requiring failure at each step prior to moving to a successive level—has been disrupted through the development and improved understanding of efficacy and risk of available options. Glaucoma is the leading cause of global irreversible blindness, and despite continued research in disease pathogenesis, all available treatment options act to reduce intraocular pressure (IOP), the key treatable risk factor for disease development and progression.
By Jessica Steen, OD
Review of Optometry CE, July 2022
Optometric Study Center: Courses published monthly in Review of Optometry and Review of Cornea & Contact Lenses, offering either 1 or 2 hours of CE credit. Processing fees apply. Exam valid for credit up to three years from release date.
Supported CE: Courses offered without exam fee, supported by an independent educational grant from a commercial interest. Typically valid for credit for one year from release date; longer active terms may exist for some exams.
Archived CE: Courses have expired but are displayed for reader interest. No credits available.